Abstracts tagged "Cardiovascular disease"

Abstract Number: 1880 • 2018 ACR/ARHP Annual Meeting
Cardiovascular (CV) Risk Factors and Atherosclerotic CV Events Among Incident Cases of Systemic Sclerosis: Results from a Population Based Cohort (1980-2016)
Avneek Singh Sandhu¹, Reto Kurmann², Cynthia S. Crowson³, Rekha Mankad², Eric L. Matteson⁴, Thomas Osborn¹, Kenneth J. Warrington⁵ and Ashima Makol¹, ¹Rheumatology, Mayo Clinic, Rochester, MN, ²Cardiovascular Diseases, Mayo Clinic College of Medicine and Science, Rochester, MN, ³Health Sciences Research, Mayo Clinic College of Medicine and Science, Rochester, MN, ⁴Division of Rheumatology, Mayo Clinic College of Medicine and Science, Rochester, MN, ⁵Rheumatology, Division of Rheumatology, Mayo Clinic College of Medicine, Rochester, MN
Background/Purpose: Cardiac involvement, due to impairment of coronary microcirculation and myocardial fibrosis, affects prognosis in individuals with SSc, and represents one of the leading causes…
Abstract Number: 2802 • 2018 ACR/ARHP Annual Meeting
Risk of Ischemic Stroke in Veterans with Systemic Sclerosis: A Nationwide Cohort Study
David Ying^1,2, Milena Gianfrancesco¹, Laura Trupin¹, Jinoos Yazdany¹, Eric Greidinger^3,4 and Gabriela Schmajuk^2,5, ¹Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, ²San Francisco VA Medical Center, San Francisco, CA, ³Medicine/Rheumatology, University of Miami Miller School of Medicine, Miami, FL, ⁴Miami VA Medical Center, Miami, FL, ⁵Medicine/Rheumatology, University of California - San Francisco, San Francisco, CA
Background/Purpose: Previously thought to involve primarily the microvasculature, systemic sclerosis (SSc) has been increasingly linked to macrovascular disease. Cardiovascular and cerebrovascular disease are responsible for…
Abstract Number: 504 • 2018 ACR/ARHP Annual Meeting
Views of Primary Care Physicians and Rheumatologists Regarding Screening and Management of Hyperlipidemia Among Patients with Rheumatoid Arthritis
Iris Navarro-Millán^1,2, Anna Cornelius-Schecter², Ronan O'Beirne³, Melanie Morris³, Susan Goodman¹, Andrea Cherrington³, Liana Fraenkel⁴, Jeffrey R. Curtis³ and Monika M. Safford², ¹Hospital for Special Surgery, New York, NY, ²Weill Cornell Medicine, New York, NY, ³University of Alabama at Birmingham, Birmingham, AL, ⁴Yale University, New Haven, CT
Background/Purpose: Screening and management of hyperlipidemia in rheumatoid arthritis (RA) is suboptimal, despite RA patients’ high risk for cardiovascular disease (CVD) mortality. Our purpose was…
Abstract Number: 788 • 2018 ACR/ARHP Annual Meeting
Clinical and Echocardiographic Associates of All-Cause Mortality and Cardiovascular Outcomes in Patients with Systemic Sclerosis
Susanne Van Wijngaarden¹, Maaike Boonstra², Bas Bloem³, Daniela Cassani⁴, Felix Tanner⁴, Suzana Jordan⁵, Oliver Distler⁶, Martin Jan Schalij³, V. Delgado¹, J.J. Bax¹, Jeska de Vries-Bouwstra⁷ and Nina Ajmone Marsan¹, ¹Heart and Lung Center, Leiden University Medical Center, Leiden, Netherlands, ²Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³Leiden University Medical Center, Leiden, Netherlands, ⁴University Heart Center, University Hospital Zurich, Zurich, Switzerland, ⁵Rheumatology, Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland, ⁶Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland, ⁷Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Cardiac events are an important cause of mortality in Systemic Sclerosis (SSc), but its diagnosis remains challenging. Left ventricular global longitudinal strain is a…
Abstract Number: 1512 • 2018 ACR/ARHP Annual Meeting
Reduction in Power Doppler Ultrasound Score with Tocilizumab Treatment Associates with Improvement in the Protective Profile of HDL in Patients with Rheumatoid Arthritis
Christina Charles-Schoeman¹, Gurjit Kaeley², Jennifer Wang³, Ani Shahbazian³, Jenny Brook⁴, David Elashoff⁴ and Veena K. Ranganath⁵, ¹Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA, ²UF Health Jacksonville, Jacksonville, FL, ³University of California, Los Angeles, Los Angeles, CA, ⁴Department of Medicine Statistics Core, UCLA David Geffen School of Medicine, Los Angeles, CA, ⁵1000 VETERAN BLVD., RM 32-59, UCLA, Los Angeles, CA
Background/Purpose: Musculoskeletal ultrasound (MSUS) can detect synovitis by Power doppler (PDUS) and can predict erosive progression on xrays in rheumatoid arthritis (RA) patients. We previously…
Abstract Number: 1881 • 2018 ACR/ARHP Annual Meeting
Discovery and Validation of Novel Disease Subsets in 806 Patients with Takayasu’s Arteritis across Four International Cohorts
Ruchika Goel¹, Katherine B. Gribbons², Kathleen Maksimowicz-McKinnon³, Gary S. Hoffman⁴, Sathish Kumar⁵, George Joseph⁶, Raheesh Ravindran⁷, Aswin Nair⁸, David Cuthbertson⁹, Simon Carette¹⁰, Nader A. Khalidi¹¹, Curry L. Koening¹², Carol Langford¹³, Carol A. McAlear¹⁴, Paul A. Monach¹⁵, Larry W. Moreland¹⁶, Christian Pagnoux¹⁷, Philip Seo¹⁸, Antoine G. Sreih¹⁹, Kenneth J. Warrington²⁰, Steven R. Ytterberg²⁰, Peter A. Merkel²¹, Debashish Danda²² and Peter C. Grayson², ¹Rheumatology, Christian Medical College, Vellore Tamilnadu, India, ²National Institute of Arthritis, Musculoskeletal and Skin Disease, National Institutes of Health, Bethesda, MD, ³Rheumatology, Henry Ford Hospital, Detroit, MI, ⁴Rheumatology, Cleveland Clinic, Cleveland, OH, ⁵Child Health, Christian Medical College, Vellore, India, ⁶Cardiology, Christian Medical College, Vellore, India, ⁷Department of Clinical Immunology and Rheumatology, Christian Medical College, Vellore, India, ⁸Clinical Immunology and Rheumatology, Christian Medical College, Vellore, India, ⁹Biostatistics and Informatics, Department of Pediatrics, Department of Biostatistics and Informatics, Department of Pediatrics, University of South Florida, Tampa, FL, ¹⁰Division of Rheumatology, Mount Sinai Hospital, Toronto, ON, Canada, ¹¹Rheumatology, McMaster University, Hamilton, ON, Canada, ¹²Rheumatology, Division of Rheumatology, University of Utah, Salt Lake City, UT, ¹³Rheumatic and Immunologic Diseases, Department of Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, ¹⁴Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ¹⁵Section of Rheumatology, Boston University School of Medicine, Boston, MA, ¹⁶Division of Rheumatology and Clinical Immunology, Division of Rheumatology, University of Pittsburgh, Pittsburgh, PA, ¹⁷Division of Rheumatology, Division of Rheumatology, Mount Sinai Hospital, Toronto, ON, Canada, ¹⁸Medicine, Division of Rheumatology, Johns Hopkins University, Baltimore, MD, ¹⁹Rheumatology, Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ²⁰Rheumatology, Division of Rheumatology, Mayo Clinic College of Medicine, Rochester, MN, ²¹University of Pennsylvania, Philadelphia, PA, ²²Clinical Immunology & Rheumatology, Christian Medical College, Vellore, India, Vellore, India
Background/Purpose: Takayasu’s arteritis (TAK) is characterized by variable patterns of damage throughout the large arteries. This study aimed to develop and validate a novel disease…
Abstract Number: 2814 • 2018 ACR/ARHP Annual Meeting
Methotrexate Use and the Risk for Cardiovascular Disease Among Rheumatoid Patients Initiating Biologic Disease-Modifying Anti-Rheumatic Drugs
Fenglong Xie¹, Lang Chen¹, Emily Levitan², Paul M. Muntner² and Jeffrey R. Curtis¹, ¹University of Alabama at Birmingham, Birmingham, AL, ²Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Methotrexate (MTX) has been associated with reduced risk for cardiovascular disease (CVD) in several studies conducted among rheumatoid arthritis (RA) patients never exposed to…
Abstract Number: 505 • 2018 ACR/ARHP Annual Meeting
Impact of Biological Treatment on Left Ventricular Regional Dysfunction in Rheumatoid Arthritis Patients Determined with Global Circumferential and Longitudinal Strain Values Using Cardiac Magnetic Resonance Imaging
Isamu Yokoe^1,2, Hitomi Kobayashi³, Yasuyuki Kobayashi⁴, Natsumi Ikumi³, Atsuma Nishiwaki⁵, Kaita Sugiyama⁶, Yosuke Nagasawa⁶, Takamasa Nozaki⁶, Noboru Kitamura² and Masami Takei², ¹Rheumatology, Kyoundo Hospital, Sasaki Institute, Tokyo, Japan, ²Division of Hematology and Rheumatology, Nihon University School of Medicine, Tokyo, Japan, ³Division of Heamatology and Rheumatology, Nihon University School of Medicine, Tokyo, Japan, ⁴Advanced Biomedical Imaging Informatics, St.Marianna University School of Medicine, Kawasaki, Japan, ⁵Hematology and Rheumatology, Nihon University School of Medicine, Tokyo, Japan, ⁶Nihon University School of Medicine, Tokyo, Japan
Background/Purpose: Congestive heart failure (CHF) is a major contributor to morbidity and mortality in patients with rheumatoid arthritis (RA). Myocardial disease is typically clinically silent,…
Abstract Number: 805 • 2018 ACR/ARHP Annual Meeting
Diastolic Dysfunction in Scleroderma: An Investigation into Associated Risk Factors and Impact on Survival
Alicia M. Hinze^1,2, Laura K. Hummers¹, Fredrick M. Wigley¹, Monica Mukherjee³ and Ami A. Shah¹, ¹Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²Division of Rheumatology, Mayo Clinic, Rochester, MN, ³Division of Cardiology, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Scleroderma heart disease often goes unrecognized until severe clinical manifestations are present. Diastolic dysfunction (DD) may identify patients at risk for cardiac complications by…
Abstract Number: 1565 • 2018 ACR/ARHP Annual Meeting
Comorbidity Burden in Primary Sjögren’s Syndrome: A Long-Term Observation in Clinical Practice
Chiara Baldini¹, Francesco Ferro¹, Nicoletta Luciano¹, Emanuele Calabresi¹, Antonella Cecchettini², Marta Mosca¹, Enzo Grossi¹ and Stefano Bombardieri¹, ¹Rheumatology Unit, University of Pisa, Pisa, Italy, ²IFC, CNR, Pisa, Italy
Background/Purpose: Primary Sjögren’s syndrome (pSS) is a complex disorder that may affect any organ and system. In this new era of personalized medicine, a growing…
Abstract Number: 1913 • 2018 ACR/ARHP Annual Meeting
Management of Ventricular Tachycardia and Cardiomyopathy in the Rheumatologist World: A Retrospective Review of Diagnostic Tools and Treatment Decisions for Cardiac Sarcoidosis
Saba Ziaee¹, Siri Kunchakarra², Cara Joyce³, Mark Rabbat⁴ and Rochella A. Ostrowski⁵, ¹Loyola University Medical Center, Maywood, IL, ²Cardiology, Loyola University Medical Center, Maywood, IL, ³Clinical Research Office, Loyola University Medical Center, Maywood, IL, ⁴Division of Cardiology, Loyola University Medical Center, Maywood, IL, ⁵Division of Rheumatology, Loyola University Medical Center, Maywood, IL
Background/Purpose: Cardiac sarcoidosis has been noted in 2-7% of patients with sarcoidosis. However, the incidence is >20% based on necropsy data. Given the poor yield…
Abstract Number: 2817 • 2018 ACR/ARHP Annual Meeting
Cardiovascular Disease Risk with Biologics and Tofacitinib Compared to Conventional Synthetic Dmards in Patients with Rheumatoid Arthritis
Gulsen Ozen¹, Sofia Pedro² and Kaleb Michaud^1,2, ¹Rheumatology, University of Nebraska Medical Center, Omaha, NE, ²FORWARD, The National Databank for Rheumatic Diseases, Wichita, KS
Background/Purpose: Cardiovascular disease (CVD) represents the leading cause of death in RA, accounting for ~50% of excess mortality. Disease activity, strongly linked to CVD, has…
Abstract Number: 507 • 2018 ACR/ARHP Annual Meeting
Echocardiographic Markers of Right Ventricle Dysfunction in Hispanic Patients with Rheumatoid Arthritis: A Case-Control Study
José R. Azpiri-López¹, Dionicio A. Galarza-Delgado², Iris J. Colunga-Pedraza³, Jose A. Davila-Jimenez⁴, Estefania E. Abundis-Marquez⁴, Andres H. Guillen-Lozoya⁴, Francisco J. Torres-Quintanilla⁴, Aldo Valdovinos-Bañuelos⁴, Ray Ramos-Cázares⁴, Raymundo Vera-Pineda⁴, Jesus A. Cardenas-de la Garza⁴, Rosa I. Arvizu-Rivera⁴ and Adrián Martínez-Moreno⁴, ¹Cardiology, Hospital Universitario, UANL, Monterrey, Mexico, ²Chief of Rheumatology, Hospital Universitario, UANL, Monterrey, Mexico, ³Rheumatology, Hospital Universitario, UANL, Monterrey, Mexico, ⁴Hospital Universitario, UANL, Monterrey, Mexico
Background/Purpose: Screening for cardiovascular (CV) disease in patients with rheumatoid arthritis (RA) remains controversial, however, there is agreement in considering echocardiography as the most immediate…
Abstract Number: 812 • 2018 ACR/ARHP Annual Meeting
Inflammatory Stays Inflammatory: A Subgroup of Systemic Sclerosis Characterized By High Morbidity and Inflammatory Resistance to Cyclophosphamide
Aleksey Mitev¹, Daria Feldmann¹, Moritz Binder², Kim Möller³, Anna-Maria Kanne¹, Thomas Hügle⁴, Peter M. Villiger⁵, Reinhard Voll⁶, Stephanie Finzel¹ and Florian Kollert⁷, ¹Department of Rheumatology and Clinical Immunology, University Medical Center Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany, ²Department of Internal Medicine, Mayo Clinic, Rochester, MN, ³Rheumatology Research Group, Institute of Inflammation and Ageing, University of Birmingham, Birmingham, United Kingdom, ⁴Rheumatology, University Hospital Lausanne (CHUV), Lausanne, Switzerland, ⁵Rheumatology and Clin Immunol, Bern, Switzerland, ⁶Clinic for Rheumatology and Clinical Immunology, University Medical Center Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany, ⁷Department of Rheumatology, Immunology, and Allergology, Inselspital, University Hospital Bern, Bern, Switzerland
Background/Purpose: Elevated levels of C-reactive protein (CRP) in systemic sclerosis (SSc) have been linked to early inflammatory stages of the disease. This study has been…
Abstract Number: 1589 • 2018 ACR/ARHP Annual Meeting
Cardiac Biomarkers and Carotid Atherosclerosis and Its Progression in Psoriatic Disease
Lihi Eder¹, Vinod Chandran², Iain B. McInnes³, Richard J. Cook⁴, Dafna D Gladman⁵, Paul Welsh⁶, Naveed Sattar⁷ and Paula Harvey⁸, ¹Women's College Research Institute, University of Toronto, Women's College Hospital, Toronto, ON, Canada, ²Krembil Research Institute & University of Toronto, Toronto, ON, Canada, ³University of Glasgow, Glasgow, United Kingdom, ⁴Statistics and Actuarial Science, University of Waterloo, Waterloo, ON, Canada, ⁵Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁶nstitute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, United Kingdom, ⁷Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, United Kingdom, ⁸Cardiology, Women's College Hospital, University of Toronto, Toronto, ON, Canada
Background/Purpose: Laboratory biomarkers indicative of cardiac ischemia or dysfunction improve cardiovascular (CV) risk stratification in the general population. Their utility in patients with psoriatic disease…

« Previous Page
1
…
4
5
6
7
8
…
38
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.